RxDoctor Payments Data

Jonathan Yeh, PA

Physician Assistant · New York, NYNPI 1457667024

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Madrigal Pharmaceuticals accounts for 71.8% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $32,658, more than ten times the $205 reported in 2021. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,286in general payments, 2019–2025

Across 227 payments — averaging $252.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$41K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$8K
  • Gilead$3K
  • Ipsen Biopharmaceuticals, Inc$2K
  • Novo Nordisk$870
  • Mallinckrodt Hospital Products Inc.$515
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$7,66013%
  • Speaking & faculty fees$33,97559%
  • Travel & lodging$6,38811%
  • Food & beverage$9,16316%
  • Gifts$1000%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,286 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$7,595
Medicare patients
48
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide52$73,769
XifaxanRifaximin17$54,676
Ursodiol66$11,995
Entecavir37$8,322
Tenofovir Disoproxil Fumarate23$5,419
Tacrolimus44$1,890
Mycophenolate Mofetil32$1,562
Spironolactone24$201
Carvedilol36$131
Omeprazole19$126
Azathioprine14$77
Pantoprazole Sodium11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$3,389$73,76952 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$7,672$54,67617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →